The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Ameliorative effect of solifenacin succinate (Vesicare®), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes

Journal of Pharmacological Sciences

Volumn 112, Issue 2, 2010, Pages 135-141

  Ohtake, Akiyoshi ^a   Sato, Shuichi ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Afferent nerve; Lower urinary tract; Muscarinic receptor; Overactive bladder; Solifenacin; Urgency

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; IMIDAFENACIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE;

BLURRED VISION; BRAIN INFARCTION; CONSTIPATION; DETRUSOR MUSCLE; DRUG EFFICACY; HUMAN; LOWER URINARY TRACT SYMPTOM; NONHUMAN; OVERACTIVE BLADDER; SALIVATION; SENSORY NERVE; SHORT SURVEY; URINARY URGENCY; UROTHELIUM; XEROSTOMIA;

EID: 77249089443     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R13FM     Document Type: Short Survey

References (24)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21: 167-178.
2. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48:531-565.
3. Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology. 2006;67:425-430.
4. Yoshida M, Masunaga K, Nagata T, Maeda Y, Miyamoto Y, Kudoh J, et al. Attenuation of non-neuronal adenosine triphosphate release from human bladder mucosa by antimuscarinic agents. LUTS. 2009;1:88-89.
5. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64:2351-2358.
6. Payne CK. Solifenacin in overactive bladder syndrome. Drugs. 2006;66:175-190.
7. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100: 579-587.
8. Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007;30:54-58.
9. Matsui M, Yamada S, Oki T, Manabe T, Taketo MM, Ehlert FJ. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci. 2004;75:2971-2981.
10. Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther. 2008;325:774-781.
11. Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol. 2007;557:154-158.
12. Ishiura Y. Experimental study of voiding dysfunction induced by cerebral infarction in rats. Jpn J Urol. 1996;87:1221-1230.
13. Suzuki M, Ohtake A, Yoshino T, Yuyama H, Hayashi A, Ukai M, et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol. 2005;512:61-66.
14. Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol. 2004;492:243-250.
15. Ohtake A, Yanai-Inamura H, Ukai M, Noguchi Y, Suzuki M, Sasamata M, et al. In vitro and in vivo bladder-selectivity profile of solifenacin succinate (Vesicare®) developed as a new therapeutic agent for overactive bladder. Jpn Pharmacol Ther. 2008;36:119-128.
16. 2+ mobilization study in monkey cells. Life Sci. 2004;74:843-853.
17. Oki T, Sato S, Miyata K, Yamada S. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol. 2005;145:219-227.
18. Oki T, Takeuchi C, Yamada S. Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice. Biol Pharm Bull. 2006;29: 1397-1400.
19. 1 -blocker coadministered with antimuscarinic drug compensates for the emptying dysfunction of the detrusor muscle. 38th Annual Meeting of the International Continence Society, 2008; abstract #405.
20. Iijima K, Wachter S, Wyndaele JJ. Effects of the muscarinic antagonist, solifenacin, on bladder afferent activity of the rat pelvic nerve. 37th Annual Meeting of the International Continence Society, 2007; abstract #192.
21. Chuang Y-C, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J. 2008;19:1353-1357.
22. Nishijima S, Kadekawa K, Miyazato M, Sugaya K. Effects of an anti-muscarinic agent and an alpha-1 receptor antagonist on plasma monoamine levels, urinary ATP level and bladder activity after bladder stimulation in rats. Neurourol Urodyn. 2008;27: 602.
23. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2009;73:14-18.
24. Cardozo L, Hebdorfer E, Milani R, Arano P, Dewilde L, Slack M, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, doubleblind, placebo-controlled, rising-dose trial. BJU Int. 2008;102: 1120-1127.